Targeting Pathophysiologic Pathways in Cervical Cancer: Why Immunotherapy?

Program Overview

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate immunotherapy rationale, mechanism of action, and safety considerations in cervical cancer.

Credit Expired

Target Audience

This activity is intended for oncology, pathology, gynecologic oncology, and OB/GYN clinicians (MD/DO/NP/PA) who treat patients with cervical cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Align the mechanism of action of immune checkpoint inhibitors with underlying cervical cancer processes

Activity Faculty

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM

Professor and Division Director
Division of Gynecologic Oncology
University of California
Irvine, CA

Featured RMEI CE Activities – Earn CE Credit(s)

New Horizons in Food Allergy: Best Practices & Treatment Advances for Unmet Needs

1.0 CE Credit(s)

Immunotherapy for NMSC: Key Insights for Oncology, Dermatology, and Infusion Nurses: A Clinical Transfers®

1.0 CE Credit(s)

Beyond the Guidelines for CMV: Clinical Perspectives on Challenging Cases Post-Transplant

1.5 CE Credit(s)

Privacy | Terms of Use